Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Atara Biotherapeutics, Inc. ATRA
$2.14
-$0.15 (-6.96%)
На 18:00, 12 мая 2023
+40.19%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
226111392.00000000
-
week52high
9.34
-
week52low
2.19
-
Revenue
63573000
-
P/E TTM
-1
-
Beta
0.94948000
-
EPS
-2.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Buy | Buy | 16 авг 2022 г. |
| Goldman Sachs | Sell | Sell | 09 авг 2022 г. |
| Citigroup | Sell | Neutral | 20 июл 2022 г. |
| Stifel | Hold | Buy | 13 июл 2022 г. |
| JP Morgan | Neutral | Overweight | 13 июл 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Koppikar Utpal | D | 191334 | 1083 | 16 ноя 2022 г. |
| Koppikar Utpal | D | 192417 | 5172 | 16 ноя 2022 г. |
| Murugan Amar | D | 127586 | 3612 | 16 ноя 2022 г. |
| Touchon Pascal | D | 441696 | 15591 | 16 ноя 2022 г. |
| Dupont Jakob | D | 154540 | 1124 | 16 ноя 2022 г. |
| Dupont Jakob | D | 155664 | 3218 | 16 ноя 2022 г. |
| Touchon Pascal | D | 457287 | 14806 | 16 авг 2022 г. |
| Koppikar Utpal | D | 197589 | 5940 | 16 авг 2022 г. |
| Murugan Amar | D | 131198 | 2234 | 16 авг 2022 г. |
| Murugan Amar | D | 133432 | 1196 | 16 авг 2022 г. |
Новостная лента
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:02
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.87 per share a year ago.
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
InvestorPlace
16 апр 2023 г. в 12:08
In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
08 февр 2023 г. в 18:49
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
04 янв 2023 г. в 16:01
THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Francis Hotel in San Francisco.
3 Under-the-Radar Biotech Stocks to Buy in 2022
The Motley Fool
24 дек 2022 г. в 10:07
The attraction of all three biotech stocks is their potential.